Tag: common

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the “Convertible Notes”). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ChampionX (CHX) To Contact Him Directly To Discuss Their Options

Reinforces Seer’s Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity

VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV, DIV.DB.A and DIV.DB.B) (the “Corporation” or “DIV”) is pleased to announce that its board of directors has approved a cash dividend of $0.02375 per common share for the period of June 1, 2026 to June 30, 2026, which is equal to $0.285 per common share on an annualized basis. The dividend will be paid on June 30, 2026 to shareholders of record as of the close of business on June 15, 2026.

TORONTO, June 03, 2026 (GLOBE NEWSWIRE) -- Kursat Kacira, the Chairman and CEO/President of Altai Resources Inc. (“Altai” or the “Company”), announced that he has disposed (the “Disposition”) of an aggregate of 11,100,000 common shares in the capital of the Company (the “Shares”). Prior to the Disposition, Mr. Kacira beneficially owned and controlled, directly and indirectly, an aggregate of 11,100,000 Shares, representing in aggregate approximately 19.8% of the total issued and outstanding Shares. After giving effect to the Disposition, Mr. Kacira does not beneficially own or control any securities in the capital of the Issuer.

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

WILMINGTON, Del., June 03, 2026 (GLOBE NEWSWIRE) -- Global Indemnity Group, LLC (NASDAQ:GBLI) (“GBLI”) announced that its Board of Directors has approved a distribution payment of $0.35 per common share to be paid on June 29, 2026 to all shareholders of record as of the close of business on June 18, 2026.